Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 13;25(12):6507.
doi: 10.3390/ijms25126507.

Emerging Roles of Exosomes in Stroke Therapy

Anthony Larson  1 , Dilmareth E Natera-Rodriguez  1 , Andrew Crane  1 , Dana Larocca  2 , Walter C Low  1 , Andrew W Grande  1   3 , Jieun Lee  4
Affiliations
Review

Emerging Roles of Exosomes in Stroke Therapy

Anthony Larson et al. Int J Mol Sci. .

Abstract

Stroke is the number one cause of morbidity in the United States and number two cause of death worldwide. There is a critical unmet medical need for more effective treatments of ischemic stroke, and this need is increasing with the shift in demographics to an older population. Recently, several studies have reported the therapeutic potential of stem cell-derived exosomes as new candidates for cell-free treatment in stoke. This review focuses on the use of stem cell-derived exosomes as a potential treatment tool for stroke patients. Therapy using exosomes can have a clear clinical advantage over stem cell transplantation in terms of safety, cost, and convenience, as well as reducing bench-to-bed latency due to fewer regulatory milestones. In this review article, we focus on (1) the therapeutic potential of exosomes in stroke treatment, (2) the optimization process of upstream and downstream production, and (3) preclinical application in a stroke animal model. Finally, we discuss the limitations and challenges faced by exosome therapy in future clinical applications.

Keywords: exosomes; stem cells; stroke; stroke therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. Lee J. was employed by UniverXome Bioengineering, Inc. (formerly known as AgeX Therapeutics, Inc.). Larocca D. was employed by the company DC Biotechnology Consulting. The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. AgeX’s legacy assets were contributed to UniverXome Bioengineering, Inc. in connection to the Merger with Serina Therapeutics Inc. UniverXome is a wholly owned subsidiary of Serina (formerly AgeX).

Figures

Figure 1
Figure 1
Schematics for the exosome application in stroke therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Mauldin P.D., Simpson K.N., Palesch Y.Y., Spilker J.S., Hill M.D., Khatri P., Broderick J.P., Interventional Management of Stroke (III) Design of the economic evaluation for the Interventional Management of Stroke (III) trial. Int. J. Stroke. 2008;3:138–144. doi: 10.1111/j.1747-4949.2008.00190.x. - DOI - PMC - PubMed
    1. Tsao C.W., Aday A.W., Almarzooq Z.I., Alonso A., Beaton A.Z., Bittencourt M.S., Boehme A.K., Buxton A.E., Carson A.P., Commodore-Mensah Y., et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation. 2022;145:e153–e639. - PubMed
    1. Adeoye O., Hornung R., Khatri P., Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: A doubling of treatment rates over the course of 5 years. Stroke. 2011;42:1952–1955. doi: 10.1161/STROKEAHA.110.612358. - DOI - PMC - PubMed
    1. Levine D.A., Duncan P.W., Nguyen-Huynh M.N., Ogedegbe O.G. Interventions Targeting Racial/Ethnic Disparities in Stroke Prevention and Treatment. Stroke. 2020;51:3425–3432. doi: 10.1161/STROKEAHA.120.030427. - DOI - PMC - PubMed
    1. Cruz-Flores S., Rabinstein A., Biller J., Elkind M.S., Griffith P., Gorelick P.B., Howard G., Leira E.C., Morgenstern L.B., Ovbiagele B., et al. Racial-ethnic disparities in stroke care: The American experience: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2091–2116. doi: 10.1161/STR.0b013e3182213e24. - DOI - PubMed